Movement Alert｜Xylem Intraday Rise 5.22% in Regular Trading, shares extend rebound despite another analyst downgrade

Market Focus11-04

On November 4, Xylem rose 5.22% in Regular Trading, trading at $101.245 per share, with turnover of $69.0946 million.

The clearest recent catalyst was a fresh analyst action: Argus Research downgraded Xylem to Hold from Buy, yet the stock continued the rebound that started after the prior session, suggesting a near-term recovery in sentiment following a sharp post-earnings selloff.

Background remains tied to the company’s October 27 quarterly report, when adjusted EPS of $1.44 and revenue of $2.20 billion both came in slightly below expectations, while full-year adjusted EPS guidance was cut to $5.40-$5.45 from $5.55-$5.70 and revenue guidance was lowered to $8.95 billion versus a $9.19 billion consensus. That reset triggered an 11% drop and a wave of sell-side cuts, including JPMorgan to Underweight with a $90 target, Barclays to Equalweight with a $104 target, and Redburn lowering its target to $129 from $165.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment